AARD
Aardvark Therapeutics, Inc. Common Stock
Biotechnology
Market Cap$79M
5Y Perf.-69.4%
Build Your Comparison
Side-by-side financial analysisAARD
IMVT
Try popular comparisons:
Stock Comparison
AARD vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$6.75B
5Y Perf.+61.7%
AARD vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  AARD |  IMVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $79M | $6.75B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-70M | $-506M |
| Total Debt | $441K | $72K |
| Cash & Equiv. | $47M | $902M |
AARD vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
AARD
IMVT
| Stock | Feb 25 | Jun 26 | Return |
|---|---|---|---|
| Aardvark Therapeuti… (AARD) | 100 | 30.6 | -69.4% |
| Immunovant, Inc. (IMVT) | 100 | 161.7 | +61.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AARD vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: IMVT leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Aardvark Therapeutics, Inc. Common Stock is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇IMVT emerged as the overall leader. Track its performance:
AARD
Aardvark Therapeutics, Inc. Common Stock
The Quality Compounder
AARD is the clearest fit if your priority is quality and efficiency.
- 4.4% margin vs IMVT's 2.6%
- -56.3% ROA vs IMVT's -62.2%
Best for: quality and efficiency
IMVT
Immunovant, Inc.
The Income Pick
IMVT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.67
- EPS growth -1.5%
- 230.5% 10Y total return vs AARD's -74.6%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  IMVT | -22.2% revenue growth vs AARD's -150.9% |
| Quality / Margins |  AARD | 4.4% margin vs IMVT's 2.6% |
| Stability / Safety | IMVT | Beta 1.67 vs AARD's 2.69, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | IMVT | +103.6% vs AARD's -67.8% |
| Efficiency (ROA) | AARD | -56.3% ROA vs IMVT's -62.2% |
AARD vs IMVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIMVTLAGGINGAARD
AARDAardvark Therapeutics…
0leads
IMVTImmunovant, Inc.
4leads
6 Total Categories
CATEGORYLEADERvs AARDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
IMVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IMVT4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT6/6
Risk & VolatilityBeta, volatility, and downside exposure
IMVT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
IMVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
AARD and IMVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | AARDAardvark Therapeu… | IMVTImmunovant, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$75M | -$532M |
| Net IncomeAfter-tax profit | -$70M | -$506M |
| Free Cash FlowCash after capex | -$62M | -$407M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -130.2% | -14.1% |
IMVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — AARD and IMVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | AARDAardvark Therapeu… | IMVTImmunovant, Inc. |
|---|---|---|
| Market CapShares × price | $79M | $6.8B |
| Enterprise ValueMkt cap + debt − cash | $33M | $5.8B |
| Trailing P/EPrice ÷ TTM EPS | -1.38x | -11.87x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.74x | 7.04x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — AARD and IMVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
IMVT leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
AARD delivers a -61.7% return on equity — every $100 of shareholder capital generates $-62 in annual profit, vs $-68 for IMVT. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to AARD's 0.00x.
| Metric | AARDAardvark Therapeu… | IMVTImmunovant, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -61.7% | -68.2% |
| ROA (TTM)Return on assets | -56.3% | -62.2% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -70.0% | -68.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 |
| Debt / EquityFinancial leverage | 0.00x | 0.00x |
| Net DebtTotal debt minus cash | -$47M | -$902M |
| Cash & Equiv.Liquid assets | $47M | $902M |
| Total DebtShort + long-term debt | $441,000 | $72,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
IMVT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $30,700 today (with dividends reinvested), compared to $2,544 for AARD. Over the past 12 months, IMVT leads with a +103.6% total return vs AARD's -67.8%. The 3-year compound annual growth rate (CAGR) favors IMVT at 14.9% vs AARD's -36.6% — a key indicator of consistent wealth creation.
| Metric | AARDAardvark Therapeu… | IMVTImmunovant, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -72.4% | +26.9% |
| 1-Year ReturnPast 12 months | -67.8% | +103.6% |
| 3-Year ReturnCumulative with dividends | -74.6% | +51.6% |
| 5-Year ReturnCumulative with dividends | -74.6% | +207.0% |
| 10-Year ReturnCumulative with dividends | -74.6% | +230.5% |
| CAGR (3Y)Annualised 3-year return | -36.6% | +14.9% |
IMVT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
IMVT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
IMVT is the less volatile stock with a 1.67 beta — it tends to amplify market swings less than AARD's 2.69 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 90.6% from its 52-week high vs AARD's 20.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AARDAardvark Therapeu… | IMVTImmunovant, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.69x | 1.67x |
| 52-Week HighHighest price in past year | $17.94 | $36.27 |
| 52-Week LowLowest price in past year | $3.35 | $14.32 |
| % of 52W HighCurrent price vs 52-week peak | +20.3% | +90.6% |
| RSI (14)Momentum oscillator 0–100 | 32.8 | 51.9 |
| Avg Volume (50D)Average daily shares traded | 155K | 1.9M |
IMVT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates AARD as "Buy" and IMVT as "Buy". Consensus price targets imply 705.8% upside for AARD (target: $29) vs 32.8% for IMVT (target: $44).
| Metric | AARDAardvark Therapeu… | IMVTImmunovant, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $29.33 | $43.67 |
| # AnalystsCovering analysts | 8 | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
IMVT leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
Best OverallImmunovant, Inc. (IMVT)Leads 4 of 6 categories
Loading custom metrics...
AARD vs IMVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is AARD or IMVT a better buy right now?
Analysts rate Aardvark Therapeutics, Inc.
Common Stock (AARD) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AARD or IMVT?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +207. 0%, compared to -74. 6% for Aardvark Therapeutics, Inc. Common Stock (AARD). Over 10 years, the gap is even starker: IMVT returned +230. 5% versus AARD's -74. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AARD or IMVT?
By beta (market sensitivity over 5 years), Immunovant, Inc.
(IMVT) is the lower-risk stock at 1. 67β versus Aardvark Therapeutics, Inc. Common Stock's 2. 69β — meaning AARD is approximately 60% more volatile than IMVT relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 0% for Aardvark Therapeutics, Inc. Common Stock — giving it more financial flexibility in a downturn.
04Which is growing faster — AARD or IMVT?
On earnings-per-share growth, the picture is similar: Immunovant, Inc.
grew EPS -1. 5% year-over-year, compared to -177. 9% for Aardvark Therapeutics, Inc. Common Stock. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AARD or IMVT?
Aardvark Therapeutics, Inc.
Common Stock (AARD) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AARD leads at 0. 0% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — AARD leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — AARD or IMVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is AARD or IMVT better for a retirement portfolio?
For long-horizon retirement investors, Immunovant, Inc.
(IMVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+230. 5% 10Y return). Aardvark Therapeutics, Inc. Common Stock (AARD) carries a higher beta of 2. 69 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IMVT: +230. 5%, AARD: -74. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between AARD and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.